Global Novel Drug Delivery Systems in Cancer Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Novel Drug Delivery Systems in Cancer Therapy Market is presumed to reach the market size of nearly USD 85.32 BN by 2030 from USD 14.48 BN in 2022 with a CAGR of 24.82% under the study period 2023 - 2030.

Novel drug delivery systems in cancer therapy aim to deliver medication in a manner that increases its concentration at a specific site relative to other parts of the body. A novel drug delivery system (NDDS) offers better patient compliance via the diminished frequency of dose. NDDS have significant advantages for cancer treatment, including improved solubility and bioavailability, reduced toxicity, maximum therapeutic effect, sustained and controlled drug delivery, increased stability and better security against physical and biochemical degradation.

MARKET DYNAMICS:

The global novel drug delivery systems in the cancer therapy market are likely to expand due to substantial benefits for cancer treatment. Also, the novel drug delivery systems market is mainly influenced by a rise in the incidences of cancer. Moreover, rise in research activities for the development of technologies of novel drug delivery coupled with augmented funding for ongoing research projects. Furthermore, a rise in healthcare expenditure for the diagnosis and treatment of cancer is likely to propel the NDDS market growth. However, the high cost of therapy may limit the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of novel drug delivery systems in cancer therapy. The growth and trends of novel drug delivery systems in cancer therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the novel drug delivery systems in cancer therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Nanoparticles (Liposomes, Polymers, Micelles, Other Nanoparticles)
Embolization Particles (Pva Particles, Drug-Eluting Beads, Liquid Emboli, Other Embolization Particles)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Novel Drug Delivery Systems in Cancer Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the novel drug delivery systems in cancer therapy market include Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., GALEN, Merrimack Pharmaceuticals Inc., Shire, Samyang Biopharmaceuticals Corporation, Celgene Corporation, Spectrum Pharmaceuticals Inc., BTG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11218543

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET ANALYSIS BY PRODUCT

6.1 Overview by Product
6.2 Historical and Forecast Data
6.3 Analysis by Product
6.4 Nanoparticles (Liposomes, Polymers, Micelles, Other nanoparticles) Historic and Forecast Sales by Regions
6.5 Embolization particles (PVA Particles, Drug-eluting Beads, Liquid Emboli, Other Embolization Particles) Historic and Forecast Sales by Regions

7 . GLOBAL NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY COMPANIES

8.1. Novel Drug Delivery Systems In Cancer Therapy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF NOVEL DRUG DELIVERY SYSTEMS IN CANCER THERAPY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Teva Pharmaceutical Industries Ltd.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Johnson & Johnson Services Inc.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. GALEN
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Merrimack Pharmaceuticals Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Shire
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Samyang Biopharmaceuticals Corporation
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Celgene Corporation
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Spectrum Pharmaceuticals Inc.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. BTG
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies